Author:
King Amanda L.,Roche Kayla N.,Leeper Heather E.,Vera Elizabeth,Mendoza Tito,Mentges Kelly,Acquaye-Mallory Alvina A.,Adegbesan Kendra A.,Boris Lisa,Burton Eric,Choi Anna,Grajkowska Ewa,Kunst Tricia,Levine Jason,Lollo Nicole,Miller Hope,Panzer Marissa,Penas-Prado Marta,Pillai Valentina,Polskin Lily,Reyes Jennifer,Sahebjam Solmaz,Stockdill Macy L.,Theeler Brett J.,Wu Jing,Gilbert Mark R.,Armstrong Terri S.
Abstract
Abstract
Purpose
Cancer patients experience distress and anxiety when undergoing imaging studies to monitor disease status, yet these symptoms are not always appropriately identified or well-managed. This interim analysis of a phase 2 clinical trial explored feasibility and acceptability of a virtual reality relaxation (VR) intervention for primary brain tumor (PBT) patients at the time of clinical evaluation.
Methods
English speaking, adult PBT patients with previous reports of distress and upcoming neuroimaging were recruited between March of 2021 and March 2022. A brief VR session was done within 2 weeks prior to neuroimaging with patient-reported outcomes (PROs) collected before and immediately post-intervention. Self-directed VR use over the next 1 month was encouraged with additional PROs assessments at 1 and 4 weeks. Feasibility metrics included enrollment, eligibility, attrition, and device-related adverse effects with satisfaction measured with qualitative phone interviews.
Results
Fifty-five patients were approached via email, 40 (73%) responded and 20 (50%) enrolled (9 declines, 11 screen fails). 65% of participants were ≤ 50 years, 50% were male, 90% were White/non-Hispanic, 85% had good KPS (≥ 90), and most were on active treatment. All patients completed the VR intervention, PROs questionnaires, weekly check-ins, and qualitative interview. Most (90%) reported frequent VR use and high satisfaction and only 7 mild AEs were recorded (headache, dizziness, nausea, neck pain).
Conclusion
This interim analysis supports feasibility and acceptability of a novel VR intervention to target psychological symptoms for PBT patients. Trial enrollment will continue to assess for intervention efficacy.
Trial Registration
NCT04301089 registered on 3/9/2020.
Funder
Division of Intramural Research, National Cancer Institute, National Institutes of Health
Intramural Continuing Umbrella of Research Experiences
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Neurology (clinical),Neurology,Oncology
Reference37 articles.
1. National Comprehensive Cancer Network (NCCN) (2002) Distress management. Practice Guidelines in Oncology. Fort Washington, PA: NCCN
2. Waller A, Groff SL, Hagen N, Bultz BD, Carlson LE (2012) Characterizing distress, the 6th vital sign, in an oncology pain clinic. Palliat Oncol 19:e53–e59
3. Howell D, Olsen K (2008) Distress: the 6th vital sign. Curr Oncol 18(5):208–210
4. Randazzo D, Peters K (2018) Psychosocial distress and its effects on the health-related quality of life for primary brain tumor patients. CNS Oncol 5(4):241–249
5. Liu F, Huang J, Zhang L et al (2018) Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis. BMC Cancer 18(124):1–8. https://doi.org/10.1186/s12885-018-3990-9
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献